Sino-Malaysian vaccine cooperation bolsters regional vaccine supply – Xinhua

0

A technician operates during a trial of the “fill and finish” process of the CanSino vaccine at the Solution Biologics factory in Kuala Lumpur, Malaysia, September 8, 2021. (Photo by Chong Voon Chung/Xinhua)

It will be possible to fill and finish some 3-6 million vaccine doses per month when production begins, with Malaysian pharmaceutical company Solution Biologics aiming to work hand-in-hand with China’s CanSino to tap into the ASEAN market and the global market as well.

KUALA LUMPUR, March 7 (Xinhua) — The close cooperation between China and Malaysia in vaccine production bodes well for the supply of COVID-19 vaccines for Malaysia and the region, officials said. drugmakers working on finalizing localized fill and finish for Chinese company CanSino Biologics. Vaccine against covid19.

The single-dose vaccine, based on the adenovirus platform, will complement other Chinese vaccines used in the Association of Southeast Asian Nations (ASEAN), especially as booster shots, said Deputy CEO of Malaysian pharmaceutical company Solution Biologics, Mohd Nazlee Kamal, told Xinhua. a recent interview.

Mohd Nazlee said it will be possible to fill and finish some 3-6 million vaccine doses per month when production begins, with Solution Biologics aiming to work hand-in-hand with CanSino to tap into the ASEAN market and the global market as well.

Malaysia approved the use of the CanSino COVID-19 vaccine in June last year, adding it to its vaccine portfolio alongside the Sinovac COVID-19 vaccine and the Sinopharm COVID-19 vaccine.

Photo shows the test of the “fill and finish” process for the CanSino vaccine at the Solution Biologics factory in Kuala Lumpur, Malaysia, September 8, 2021. (Photo by Chong Voon Chung/Xinhua)

In February, Solution Biologics received Good Manufacturing Practices approval from the National Drug Regulatory Agency to locally formulate and fill and complete the CanSino COVID-19 vaccine.

Several ASEAN countries also use vaccines developed by China as part of their national immunization programs, including Indonesia, Thailand, Cambodia and the Philippines.

CanSino Biologics External Vice President of R&D Xin Chunlin said the CanSino injectable vaccine and its inhaled form, which is being tested, would provide more effective vaccination for the public.

He said the inhaled form of the vaccine is more flexible, using a fifth of the formulation of the injectable version, and can remain stable for almost a month at room temperature.

Xin, together with Wang Hongyi, Vice President of International Affairs of CanSino, visited several countries, including Mexico, Pakistan, Malaysia and Indonesia, countries that Mr. Wang said were keen to cooperate with China to obtain the technology.

A technician operates during a trial of the “fill and finish” process of the CanSino vaccine at the Solution Biologics factory in Kuala Lumpur, Malaysia, September 8, 2021. (Photo by Chong Voon Chung/Xinhua)

Elaborating on the importance of localized fill-and-finish production of adenovirus vaccines in Malaysia, Genome and Vaccine Institute Director Ghows Azzam said the move would be a game-changer for Malaysia. , which seeks to develop and manufacture its own vaccines.

Ghows said the close cooperation between China and Malaysia has helped the country boost its vaccine capacity.

“Government support and of course the good relationship with the Chinese government will definitely help us catalyze our innovation in vaccine development,” he said.

Share.

Comments are closed.